INMUNE BIO INC. (INMB) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $28.00K; Additional Paid in CapitalUSD $237.69M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-823.00K; Retained Earnings (Accumulated Deficit)USD $-215.72M.
- 2026-03-31: Common Stock, Value, IssuedUSD $27.00K; Additional Paid in CapitalUSD $234.77M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-727.00K; Retained Earnings (Accumulated Deficit)USD $-214.44M.
- 2025-12-31: Common Stock, Value, IssuedUSD $27.00K; Additional Paid in CapitalUSD $233.27M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-737.00K; Retained Earnings (Accumulated Deficit)USD $-209.04M.
- 2025-09-30: Common Stock, Value, IssuedUSD $27.00K; Additional Paid in CapitalUSD $229.89M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-764.00K; Retained Earnings (Accumulated Deficit)USD $-203.77M.
INMUNE BIO INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $28.00K | $237.69M | $-823.00K | $-215.72M | $20.36M | 3 month · $1.36M | (m) | (m) |
| 2026-03-31 | $27.00K | $234.77M | $-727.00K | $-214.44M | $19.62M | 3 month · $1.50M | (m) | (m) |
| 2025-12-31 | $27.00K | $233.27M | $-737.00K | $-209.04M | $23.52M | 12 month · $9.91M | (m) | (m) |
| 2025-09-30 | $27.00K | $229.89M | $-764.00K | $-203.77M | $25.38M | 3 month · $2.98M | (m) | (m) |
| 2025-06-30 | $27.00K | $226.90M | $-763.00K | $-197.30M | $28.87M | 3 month · $1.53M | (m) | (m) |
| 2025-03-31 | $23.00K | $203.10M | $-610.00K | $-172.84M | $29.67M | 3 month · $2.08M | (m) | (m) |
| 2024-12-31 | $22.00K | $195.75M | $-575.00K | $-163.10M | $32.10M | 12 month · $7.61M | (m) | (m) |
| 2024-09-30 | $22.00K | $193.57M | $-1.04M | $-153.89M | $38.67M | 3 month · $1.72M | (m) | (m) |
| 2024-06-30 | $20.00K | $178.77M | $-713.00K | $-141.79M | $36.28M | 3 month · $2.35M | (m) | (m) |
| 2024-03-31 | $18.00K | $160.92M | $-669.00K | $-132.05M | $28.22M | 3 month · $1.78M | (m) | (m) |
| 2023-12-31 | $18.00K | $159.14M | $-799.00K | $-121.02M | $37.34M | 12 month · $7.37M | (m) | (m) |
| 2023-09-30 | $18.00K | $157.26M | $-735.00K | $-112.61M | $43.93M | 3 month · $1.89M 9 month · $5.49M | (m) | (m) |
| 2023-06-30 | $18.00K | $155.40M | $-712.00K | $-104.05M | $50.65M | 3 month · $1.86M 6 month · $3.60M | $50.65M | (m) |
| 2023-03-31 | $18.00K | $153.54M | $-708.00K | $-97.55M | $55.30M | 3 month · $1.74M | $55.30M | (m) |
| 2022-12-31 | $18.00K | $151.80M | $-699.00K | $-91.01M | $60.10M | 12 month · $7.15M | $60.10M | (m) |
| 2022-09-30 | $18.00K | $150.01M | $-1.14M | $-85.18M | $63.71M | 3 month · $1.94M 9 month · $5.36M | $63.71M | (m) |
| 2022-06-30 | $18.00K | $148.07M | $-701.00K | $-77.46M | $69.93M | 6 month · $3.42M | $69.93M | (m) |
| 2022-03-31 | $18.00K | $146.19M | $56.00K | $-70.62M | $75.64M | 3 month · $1.89M | $75.64M | (m) |
| 2021-12-31 | $18.00K | $143.92M | $1.00K | $-63.72M | $80.22M | (m) | $80.22M | (m) |
| 2021-09-30 | $18.00K | $142.40M | $-118.00K | $-54.04M | $88.25M | (m) | (m) | (m) |
| 2021-06-30 | $15.00K | $87.85M | $-50.00K | $-44.59M | $43.23M | (m) | (m) | 3 month · $769.00K |
| 2021-03-31 | $15.00K | $101.47M | $12.00K | $-37.93M | $63.56M | (m) | (m) | 3 month · $899.00K |
| 2020-12-31 | $13.00K | $72.11M | $11.00K | $-33.38M | $38.75M | (m) | $38.75M | 12 month · $3.11M |
| 2020-09-30 | $13.45K | $71.35M | $-37.73K | $-30.17M | $41.21M | (m) | (m) | 3 month · $1.05M |
| 2020-06-30 | $10.90K | $47.07M | $10.13K | $-25.45M | $21.68M | (m) | (m) | 3 month · $681.00K |
| 2020-03-31 | $10.75K | $45.72M | $-29.25K | $-23.35M | $22.41M | (m) | (m) | 3 month · $682.00K |
| 2019-12-31 | $10.77K | $44.83M | $-8.52K | $-21.28M | $23.61M | (m) | (m) | 12 month · $4.10M |
| 2019-09-30 | $10.76K | $43.66M | $-54.75K | $-18.96M | $24.71M | (m) | (m) | 3 month · $974.70K |
| 2019-06-30 | $10.76K | $42.69M | $-19.21K | $-15.89M | $26.84M | (m) | (m) | 3 month · $974.70K |
| 2019-03-31 | $9.74K | $33.67M | $5.81K | $-15.50M | $22.86M | (m) | (m) | 3 month · $974.70K |
| 2018-12-31 | $8.72K | $25.45M | $6.53K | $-13.60M | $16.54M | (m) | (m) | 12 month · $5.38M |
| 2018-09-30 | (m) | (m) | (m) | (m) | $17.47M | (m) | (m) | 3 month · $979.56K |
| 2018-06-30 | (m) | (m) | (m) | (m) | $18.03M | (m) | (m) | 3 month · $979.56K |
| 2018-03-31 | (m) | (m) | (m) | (m) | $18.63M | (m) | (m) | 3 month · $2.46M |
| 2017-12-31 | $8.32K | $19.17M | $32.04K | $-1.16M | $18.10M | (m) | (m) | 12 month · $199.56K |
| 2016-12-31 | (m) | (m) | (m) | (m) | $-149.20K | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |